Digestive cancer risk can be curbed with daily asprin use

New Delhi: People who are at the threat of digestive cancer can reduce its risk by relying on a daily dose of asprin, says a study.

Individuals who regularly use pain reliever aspirin are likely to experience a significant reduction in digestive cancer risk, found a study involving over 600,000 people.

The patients who were prescribed aspirin daily showed a 47 per cent reduction in liver and oesophageal cancer incidence.

Gastric cancer reduced by 38 per cent, pancreatic cancer by 34 per cent while colorectal cancer by 24 per cent, it said.

Digestive cancer, although not so widely prevalent, still accounts for numerous deaths across the globe.

Colorectal, gastric and pancreatic cancer are within the top five cancer killers throughout the continent, with digestive cancers representing 30.1 per cent of cancer deaths.

The effect of long-term use of aspirin is also seen in significant reduction in leukaemia, lung and prostate cancers and some breast, bladder, kidney and multiple myeloma cancers.

Whilst the use of aspirin is debated within the medical community, a recent study also found that patients who stopped taking aspirin were 37 per cent more likely to have an adverse cardiovascular event, such as a heart attack or stroke.

With Agency inputs